Methylergonovine
متیلارگونووین (متِرژن)
🚻 Genito Urinary System And Sex HormonesErgot alkaloid uterotonic
Market / country: 🇺🇸 USA
Methergine (US)
🧮 Dose calculator
Postpartum haemorrhage / uterine subinvolution · Regimen source: FDA Methylergonovine · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypertension; toxaemia (pre-eclampsia); pregnancy; hypersensitivity. FDA Methylergonovine · Contraindications
Important interactions
- • With strong CYP3A4 inhibitors (clarithromycin, erythromycin, ritonavir, ketoconazole) risk of serious vasospastic ischaemia. FDA Methylergonovine · Precautions — Drug Interactions
Formulations
- 0.2 mg tablet — tablet 🇺🇸 USA FDA Methylergonovine · How Supplied
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Methylergonovine · CONTRAINDICATIONS
“Hypertension; toxemia; pregnancy; and hypersensitivity.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Methylergonovine · Nursing Mothers
“Mothers should not breast-feed during treatment with methylergonovine maleate and at least 12 hours after administration of the last dose.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Methylergonovine · Pediatric Use
“Safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Methylergonovine · Geriatric Use
“In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA210424
- DailyMed (FDA label)FDA Methylergonovine
- MedlinePlus (NIH)Methylergonovine
- WHO ATC/DDDG02AB01
- Darooyab (Iran)Methylergonovine-Maleate
🇮🇷 Registered in Iran Darooyab · G-4015/Methylergonovine-Maleate
Dosage forms with Iranian generic codes, per Darooyab.
- 00833 · METHYLERGONOVINE MALEATE 0.125MG TAB · قرص متیلرگونووین مالئات ۰٫۱۲۵ میلیگرم
- 00834 · METHYLERGONOVINE MALEATE 0.2MG/1ML AMP · آمپول متیلرگونووین مالئات ۰٫۲ میلیگرم / ۱ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Methylergonovine · How SuppliedFDA Methylergonovine · Dosage and AdministrationFDA Methylergonovine · ContraindicationsFDA Methylergonovine · Precautions — Drug InteractionsFDA Methylergonovine · CONTRAINDICATIONSFDA Methylergonovine · Nursing MothersFDA Methylergonovine · Pediatric UseFDA Methylergonovine · Geriatric UseFDA Methylergonovine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4015/Methylergonovine-Maleate
- Clinical review⚠ Unverified